Navigation Links
Boston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2010
Date:2/1/2011

cted procedural volumes; new product approvals, launches and sales; regulatory compliance; our market position; cash flow; write-down of goodwill and other asset impairments; our capacity to fund acquisitions and other investments and to successfully complete acquisitions and integrate them into our business; our ability to successfully separate our Neurovascular business; our ability to reduce our debt obligations; and our restructuring activities.
If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.
These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.
As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions and the market acceptance of those products; clinical trial results; demographic trends; intellectual property; litigation; financial market conditions; the effect of our goodwill impairment charges and our restructuring initiatives; closing of announced acquisitions and integration of acquired companies; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - 
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System
2. Boston Scientific Responds to DOJ Civil Lawsuit
3. Boston Scientific Announces First Use of Blazer® Open-Irrigated Catheter in U.S.
4. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
5. Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent
6. Boston Scientific Announces Agreement With Fukuda Denshi for Distribution of Cardiac Rhythm Management Products in Japan
7. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2010 Financial Results
8. Boston Scientific to Acquire Atritech
9. Boston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease
10. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
11. Boston Scientific Completes Acquisition of Sadra Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... leading OTC brands from GSK in an all cash ... clear demonstration of Perrigo,s unique ability to maximize brand ... 36 countries.  Perrigo Chairman, President and ... excited to complete this transaction, which clearly demonstrates our ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... Medical, Inc. (Solta) (Nasdaq: SLTM ), ... today announced that Medicis Technologies Corporation (formerly LipoSonix, ... has received U.S. Food and Drug Administration (FDA) ... indicated for non-invasive waist circumference reduction. The LipoSonix ...
... SPRING, Md., Oct. 24, 2011 The U.S. ... generic versions of Zyprexa (olanzapine tablets) and Zyprexa ... and bipolar disorder. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... and disabling brain disorder. About 1 percent of ...
Cached Medicine Technology:Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System 2Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System 3Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System 4Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System 5FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 2FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 3
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been a licensed ... "I specialize in manual therapy, and my invention will provide headache sufferers a ... additional muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates ...
(Date:8/29/2015)... ... ... Next weekend is Labor Day weekend, the last bash of the season ... year). For IT security personnel, it should also mark the perfect time to make ... than a simple headache. , Joe Caruso, founder and CEO-CTO of Global Digital ...
(Date:8/29/2015)... TX (PRWEB) , ... August 29, 2015 , ... ... allows the company to freely market and sell Arterosil and Arterosil HP, and ... Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment ... position they are applying for, they are unable to pass the initial drug test ... drug testing policies in order to be able to hire long-term, skilled talent. (1) ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a non-invasive ... two years, the longest of any cellulite reduction system currently on the market. ... solution for their cellulite, according to Dr. Robert Weiss, director of the premier MD ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... said on Friday that more than 300 people reported ill ... Olive Garden restaurant at Indianapolis// last weekend, a day after ... restaurants. ,The restaurant is closed temporarily and health ... ,Leftover food and stool samples were collected ...
... prevalence of obesity could bankrupt the health system, warn doctors ... over half the population is overweight and more than one ... Obese people are at high risk of multiple health problems, ... is currently estimated at up to 9%, and the overall ...
... Supplement, a product containing the drug estazolam, which might make ... months. // ,Estazolam belongs to benzodiazepines class of ... as it may have a number of side effects like ... is not legal to sell it in Canada. ,Hence, ...
... pneumonia in the Downtown Eastside with more than 70 cases ... Downtown Eastside has clearly pushed the health supporting system to ... memo, David Butcher, vice-president of medicine for Northern Health, warned ... limiting the availability of ICU beds. ,"At the ...
... a weekend night over, ice has become an integral part of ... drugs used by people along with ice are marijuana, ketamine, heroin ... mask the effects of these drugs when they have report to ... pleasurable sensation in my head, after which they usually smoke ice ...
... Expression of two different proteins taken from primary tumor ... to nearby lymph nodes, according to researchers who// say ... stage those patients whose disease is likely to metastasize. ... Research, the researchers say over-expression of one unidentified protein ...
Cached Medicine News:Health News:Obesity Could Bankrupt the Health System, Warn Doctors 2Health News:Researchers Find Two Biomarkers With Potential to Predict Breast Cancer Spread 2Health News:Researchers Find Two Biomarkers With Potential to Predict Breast Cancer Spread 3Health News:Researchers Find Two Biomarkers With Potential to Predict Breast Cancer Spread 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: